Dr Aurelio Castrellon speaks to ecancer at the 2019 ASCO Direct Highlights Symposium in Miami about the important developments in the treatment of hormone receptor-positive HER2-negative breast cancer.
He describes two main studies in patients with stage IV breast cancer, specifically in premenopausal patients and includes the MONALEESA-7 trial and the KCSG-BR 15-10 study.
Dr Castrellon also details two further studies which assessed the use of pembrolizumab combined with eribulin in this disease setting and the combination of fulvestrant with capivasertib (an AKT-inhibitor).
He concludes by mentioning the mutation FAT1, which may confer intrinsic resistance to CDK4/6 inhibition in these patients.